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Purpose: When comparing chronic obstructive lung disease (COPD) interventions in database 
research, it is important to adjust for severity. Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) guidelines grade severity according to lung function. Most databases lack data 
on lung function. Previous database research has approximated COPD severity using demo-
graphics and healthcare utilization. This study aims to derive an algorithm for COPD severity 
using baseline data from a large respiratory trial (UPLIFT).
Methods: Partial proportional odds logit models were developed for probabilities of being in 
GOLD stages II, III and IV . Concordance between predicted and observed stage was assessed 
using kappa-statistics. Models were estimated in a random selection of 2/3 of patients and 
validated in the remainder. The analysis was repeated in a subsample with a balanced distribu-
tion across severity stages. Univariate associations of COPD severity with the covariates were 
tested as well.
Results: More severe COPD was associated with being male and younger, having quit smoking, 
lower BMI, osteoporosis, hospitalizations, using certain medications, and oxygen. After adjust-
ing for these variables, co-morbidities, previous healthcare resource use (eg, emergency room, 
hospitalizations) and inhaled corticosteroids, xanthines, or mucolytics were no longer indepen-
dently associated with COPD severity, although they were in univariate tests. The concordance 
was poor (kappa = 0.151) and only slightly better in the balanced sample (kappa = 0.215).
Conclusion: COPD severity cannot be reliably predicted from demographics and healthcare 
use. This limitation should be considered when interpreting findings from database studies, and 
additional research should explore other methods to account for COPD severity.
Keywords: GOLD, healthcare resource use, partial proportional odds logit
Introduction
Treatment effectiveness and healthcare resource use in daily practice may be different 
from effectiveness and resource use in clinical trials. This is increasingly recognized 
by researchers, policy makers and decision makers responsible for pricing and reim-
bursement of healthcare interventions. Hence, the importance of data generated from 
sources that reflect the use and the associated outcomes in routine practice settings 
is growing. Suitable sources of such real-life data could be health records kept by 
physicians (eg, their routine records or specifically established databases; paper-based 
or electronic), patient registries that enroll patients with specific diseases or other 
characteristics of interest (eg, cancer registries), or administrative claims databases of 
healthcare insurers and provider organizations set up for the purpose of reimbursement 
of providers for their expenses.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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The inherent problem of analyses conducted on such   
databases relates to the fact that the data are often collected 
for other purposes. When treatment is not assigned to patients 
at random, disease severity and prognosis of patients may 
differ systematically across treatments. In order to adjust for 
this, data that reflect disease severity must be available.
The currently most widely used severity classification 
is the spirometric classification of the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD),1 which is based 
on lung function in terms of the forced expiratory volume 
in one second as a percentage of the value predicted for sex, 
age and height (FEV1-%predicted). It is used to diagnose 
COPD, to monitor disease progression and to aid in treat-
ment decisions. Lung function is an important indicator 
of COPD severity because it is associated with mortality,2 
exacerbations,3,4 health care utilization and costs.5 There is 
also an association between lung function and quality of life6 
although this relationship is not as strong.7,8 Consequently, 
the same associations have been shown for the GOLD clas-
sification as it is based on FEV1.9–13
It is widely recognized, also by GOLD,1 that the impact 
of COPD does not only depend on lung function and further-
more that is not only a lung disease but a multi-dimensional 
disease with many systemic, extra-pulmonary effects. 
Therefore, composite measures of COPD severity have 
been proposed. However, almost all of these still accept the 
importance of airflow limitation and they are partly based 
on the FEV1-%predicted.14–18
However, lung function measures obtained through 
spirometry are not routinely available in databases and 
  registries. Most routine databases also lack information on 
the other parameters that constitute the more recent composite 
measures of COPD severity. Previous retrospective database 
research has approximated COPD severity using demographic 
(eg, age and/or smoking status) and resource utilization data 
(eg, medications used and/or hospital admission).19–24
In this study, we attempted to develop a multivariable 
predictive algorithm to derive the severity of COPD as classi-
fied by GOLD, using variables that are commonly available in 
routine databases. The analysis was performed on the baseline 
data of the “Understanding Potential Long-term Impacts on 
Function with Tiotropium” (UPLIFT) trial, a large, 4-year 
trial in COPD patients with rate of decline in FEV1 as primary 
endpoint.25 This trial was especially suitable for this purpose 
because of its size (with almost 6000 patients randomized), 
and because among the baseline data collected are many data 
commonly available in routine databases (eg, demographics, 
medications used in the past, hospital admissions in the year 
preceding enrollment). Moreover, FEV1 was collected with 
high quality, thus providing confidence in the GOLD severity 
assignment of trial patients.
Material and methods
Data source
We used baseline data from the UPLIFT trial. The UPLIFT 
trial was a randomized, double-blind, placebo-controlled 
4-year trial, investigating the effect of tiotropium on the yearly 
rate of decline in FEV1 in patients with moderate to very 
severe COPD according to GOLD (stages II to IV).   Patients 
were permitted to use all respiratory   medications except 
inhaled anticholinergics. 5993 patients were   randomized.25 
Main inclusion criteria besides a diagnosis of COPD 
included age of 40 years or over, a smoking   history of at least 
10 pack-years, a post-bronchodilator FEV1-%predicted of 
70% or less, and an FEV1 of 70% or less of the forced vital 
capacity. Key exclusion criteria were a history of asthma, a 
COPD exacerbation or respiratory   infection within 4 weeks 
before screening, use of supplemental oxygen for more than 
12 hours per day. UPLIFT collected information on patients’ 
demographics, comorbidities and co-medications as well 
as COPD characteristics and   smoking history, along with 
contacts with health care providers in various settings in the 
year preceding enrollment.
In order to enhance the homogeneity of treatment pat-
terns, the sample was limited to 3698 patients from Western 
Europe, the United States, Australia and New Zealand with 
COPD severity stage II, III or IV . The sample was randomly 
split into two sets: one for developing the algorithm (2/3 of 
patients) and the other for validation (1/3 of patients).
selection of variables
Potential variables for inclusion in the algorithm to 
approximate disease severity were those used in previous 
database research and those used in diagnostic and sever-
ity classifications.14–17,26–29 Variables were then selected if 
available in UPLIFT and likely to be available in routine 
databases. The final list of variables to be tested consisted 
of age (continuously in years, squared, and in categories: 
40–49, 50–59, 60–69, 70–79, 80–90, 90+). BMI (con-
tinuously and categorized: ,18.5, 18.5–21.0, 21.0–25.0, 
25.0–30.0, .30.0), smoking status (current/former smoker), 
pack-years of smoking (continuously and categorized: ,20, 
20–60, .60), sex, type of respiratory maintenance medica-
tions (short-acting and long-acting bronchodilators, inhaled 
corticosteroids (ICS), mucolytics, leukotriene modifiers, 
xanthine), number of medication types (0 to 5), treatment International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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of exacerbations (number of courses of antibiotics or oral 
steroids, categorized: 0, 1, 2, $3 in one year), resource use 
in one year (number of emergency room visits with/with-
out hospital admission, categorized (0, 1, $2), number of 
  scheduled and unscheduled general practitioner (GP) visits 
(categorized: 0, 1, 2, 3–4, $5 and 0, 1, 2, $3, respectively), 
hospital admissions (yes/no), use of oxygen at home (yes/
no), statin use (yes/no), use of other cardiovascular medica-
tion (yes/no), number of co-morbidities (categorized: 0, 1, 2, 
3–5, 6–9, $10), Charlson comorbidity index30 (categorized: 
1, 2, 3, $4), presence of selected co-morbidities (arrhyth-
mia, coronary heart disease, vascular disease, hypertension, 
disorders of nervous system, stroke, diabetes, depression, 
anemia, and platelet disorders, osteoporosis and cataract), 
as well as interaction terms (age × gender, age × BMI, 
BMI × gender).
Analysis
Several partial proportional odds (PPO) ordered logit 
models were used to estimate the probabilities of being in 
GOLD stages II (FEV1%-predicted .50%), III (FEV1%-
predicted FEV1%-predicted 30%–50%), and IV (FEV1%-
predicted ,30%), as COPD severity categories are ordered. 
The “development dataset” was used for this purpose.
The PPO resembles the standard ordered logit model, 
which is the best-known ordered regression model. In our 
case, with three possible outcomes Y, it estimates the prob-
ability that Y . stage II and the probability that Y . stage III. 
Ordered regression models assume that the observed ordered 
outcome Y is a function of a continuous and unobservable 
variable Y*. Two thresholds τj are assumed to determine in 
which stage a patient is classified: Y . Yj if Y* .τj, where 
j denotes a specific outcome and tj is the upper limit of Y* 
for this outcome. Y* is related to the explanatory variables X: 
YX ii ji j *=+ βε , where i denotes individual patients. Since 
the latent variable Y* does not completely equal the sum of 
the products of coefficients and variable values, the outcome 
Y cannot be determined with certainty from the data. Assum-
ing a logit distribution for the random error term makes it 
possible to model the probability that a patient is in a certain 
stage or worse (Y* . τj). This probability may be written as: 
Pr() exp( )/ exp( ) Yj XX ij ij ji j  =− ++ −+ τβ τβ 1 ,  j = 1, 
2, …, M − 1. M is the number of possible outcomes.
In contrast to the PPO model, however, the ordered logit 
model can only estimate one coefficient for each explana-
tory variable. This coefficient is assumed to be identical for 
all dichotomizations of the outcome variable (in this case, 
stage IV versus II/III and stage III/IV versus II), and thus 
coefficient βj = β. This is the proportional odds or   parallel 
regressions assumption. If this assumption is violated, 
which often happens in practice, estimates are invalid 
and important differences in the relationships at different 
thresholds may go unnoticed. The partial proportional odds 
model relaxes this assumption for variables where it does 
not hold.31 For these variables, a coefficient is estimated for 
each dichotomization.
The final model was developed by stepwise back-
ward elimination from the full model, which contained 
all variables. In each step the variable with the largest 
P-value was eliminated and the model was re-estimated. 
This process was repeated until all variables had at least 
a value of P # 0.10.
We performed two sensitivity analyses in order to 
account for the fact that the proportion of patients with very 
severe COPD (GOLD IV) in the dataset was smaller than 
the proportion of patients with moderate or severe COPD. 
Firstly, the final model was re-estimated in a sub-sample 
with a balanced distribution of patients across all three 
severity stages. This balance was achieved by using all 
GOLD stage IV patients and random draws from patients 
in stages II and III. Secondly, the patients in GOLD stage 
III and IV were combined into one group. The probability 
of being in ‘severe/very severe’ was then analyzed in a 
binary logit model with the same variables as in the final 
PPO model.
All analyses were performed in Stata 11.1, (StataCorp 
LP, College Station, TX) using the gologit2 command for 
the PPO model.32 Univariate tests were analysis of variance 
(ANOVA) for continuous variables and chi-square for cat-
egorical variables. Statistical significance was reached when 
a two-sided P-value was #0.05.
Predictive performance
The regression results were used to predict the probabilities 
of being in each GOLD severity stage for each patient in the 
validation dataset. The predicted stage was defined as the stage 
with the highest predicted probability. The agreement between 
the predicted and the observed stage was assessed using kappa 
statistics.33 For a kappa statistic, a value of 0 indicates that 
agreement has occurred by chance, whereas a value of 1 indi-
cates perfect agreement. No generally accepted interpretation 
of the magnitude of the kappa-statistic exists. Landis and 
Koch suggested the following labels of agreement for ranges 
of values, which are often quoted: slight (up to 0.20), fair 
(0.21–0.40), moderate (0.41–0.60), substantial (0.61–0.80), 
and almost perfect (0.81–1.0).34 We present kappa statistics International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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unweighted and weighted. In the weighted kappa statistics, 
patients misclassified in the neighboring category (ie, II 
or IV instead of III, or III instead of II or IV) count as 0.5 
agreement and patients misclassified in a   non-neighboring 
category (II instead of IV or vice versa) as no agreement).
In addition to the agreement per disease stage, the overall 
agreement was calculated. For the binary logit model, the 
c-statistic was computed as a measure of its discriminative 
performance. The c-statistic represents the area under the 
receiver operating characteristic (ROC) curve, a plot of 
sensitivity against specificity. Values can range from 0.5 (no 
predictive ability) to 1 (perfect discrimination).
Table 1A Patient characteristics, risk factors, and comorbidity per GOLD stage in full sample (development and validation sets 
combined)
Stage II 
n = 1720  
(47%)
III 
n = 1640  
(44%)
IV 
n = 338  
(9%)
P-value*
Age (sD) 64.9 (8.47) 65.8 (7.98) 63.0 (8.23) 0.000
Male 70.10% 72.80% 75.40% 0.066
BMI , 21 9.94% 12.56% 26.63% 0.000
BMI . 25 62.15% 56.58% 34.61%
Underweight (BMI , 18.5) 2.44% 3.84% 10.06% 0.000
Low weight (18.5 . BMI , 21) 7.50% 8.72% 16.57%
normal BMI 27.91% 30.85% 38.76%
Overweight (25 , BMI , 30) 36.92% 36.45% 23.37%
Obese (BMI . 30) 25.23% 20.12% 11.24%
Current smoker 33.43% 28.23% 27.51% 0.002
,20 Pack years 6.63% 5.85% 7.69% 0.700
20–60 pack years 66.86% 66.95% 64.79%
.60 pack years 26.51% 27.20% 27.51%
Comorbidities
 0 12.67% 12.20% 11.54% 0.752
 1 14.59% 15.30% 17.46%
 2 15.52% 14.27% 12.72%
  3–5 27.38% 27.80% 29.29%
  6–9 18.31% 29.29% 19.82%
Charlson comorbidity index
 1 69.36% 69.51% 74.56% 0.398
 2 21.28% 21.16% 15.98%
 3 6.40% 5.91% 5.92%
  $4 2.97% 3.41% 3.55%
Coronary heart disease 14.13% 13.41% 12.43% 0.657
Vascular disease 45.29% 43.78% 38.46% 0.067
hypertension 41.05% 40.00% 35.50% 0.163
nervous system disorders 14.65% 14.45% 15.68% 0.844
stroke 0.41% 0.39% 0.30% 0.865
Diabetes 9.24% 8.35% 5.92% 0.126
Depression 10.64% 10.24% 11.54% 0.768
Anemia 0.93% 1.10% 0.30% 0.381
Platelet disorders 0.29% 0.18% 0.00% 0.533
Osteoporosis 5.64% 8.54% 8.28% 0.004
Cataract 2.50% 2.32% 3.55% 0.419
Note: *Two-sided P-values from analysis of variance for continuous variables and from the chi-squared test for categorical variables.
Abbreviations: BMI, body mass index; sD, standard deviation; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Lastly, in an analysis of correctly and incorrectly classi-
fied patients, the average values of FEV1%-predicted were 
compared per severity stage.
Results
Description of sample
Patient characteristics are summarized in Table 1A, demon-
strating that 47% were in GOLD stage II, 44% in stage III, 
and 9% in stage IV . Patients in more severe disease states 
were more likely to have a lower BMI, to have quit smoking 
and to suffer from osteoporosis. The mean age of patients 
in stage IV was 2–3 years lower than in the less severe International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Table 1B Medication per GOLD stage in full sample (development and validation sets combined)
Stage II 
n = 1720  
(47%)
III 
N = 1640  
(44%)
IV 
n = 338  
(9%)
P-value*
no short-acting bronchodilators 33.78% 20.91% 13.31% 0.000
1 short-acting bronchodilator 36.10% 37.56% 26.04%
2 short-acting bronchodilators 30.12% 41.52% 60.65%
Long-acting bronchodilator (yes/no) 62.03% 70.55% 75.74% 0.000
Inhaled corticosteroids (yes/no) 62.21% 69.51% 76.33% 0.000
Other steroids (yes/no) 5.76% 10.00% 17.16% 0.000
Xanthine (yes/no) 9.94% 19.33% 20.12% 0.000
Leukotriene modifier (yes/no) 2.79% 5.67% 8.58% 0.000
Mucolytics 4.19% 5.85% 5.33% 0.084
home oxygen (yes/no) 1.05% 3.05% 9.17% 0.000
statins (yes/no) 19.13% 16.52% 13.61% 0.020
Cardiovascular medication (yes/no) 51.16% 54.82% 48.82% 0.020
Courses of oral steroids
 0 70.76% 59.45% 52.66% 0.000
 1 17.44% 22.68% 23.08%
 2 6.22% 9.02% 8.84%
  $3 5.58% 8.84% 11.54%
Courses of antibiotics
 0 53.31% 44.27% 43.20% 0.000
 1 22.97% 24.94% 25.15%
 2 12.91% 16.10% 16.27%
  $3 10.81% 14.70% 15.38%
Note: *Two-sided P-values from the chi-squared test for categorical variables.
Abbreviation: GOLD, Global Initiative for Chronic Obstructive Lung Disease.
  categories. The disease stage was not significantly associated 
with pack-years, the number of co-morbidities, Charlson’s 
comorbidity index, and various concomitant diseases.
Tables 1B and C show that disease stage was associated 
significantly with almost every type of medication and resource 
use. Patients with more severe COPD were more likely to use 
various types of pulmonary maintenance   medication, oxygen 
at home, exacerbation medication, consult their GP more often 
(on a scheduled and unscheduled basis), visit the emergency 
room with resulting admission more often, and were more 
likely to have been admitted for any reason to the hospital in the 
last year. The use of statins and other cardiovascular medica-
tion was more frequent in patients with less severe disease.
There was no difference between the dataset used for 
developing the algorithm and the validation dataset.
regression results
In the final model (Table 2), the parallel regression assump-
tion was violated for five variables (age, gender, xanthine 
and oxygen use, and two categories of the BMI variable, 
  overweight and obese). In these cases, a coefficient was esti-
mated for each dichotomization (GOLD III/IV versus GOLD 
II and GOLD IV versus GOLD II/III). For all other variables, 
one coefficient was estimated for both dichotomizations.
In the multivariable analysis, a higher risk of more severe 
COPD was significantly associated with being younger, being 
male, having a lower BMI, having quit smoking, suffering from 
osteoporosis, using oxygen, courses of oral steroids, having been 
hospitalized in the previous year, and certain types of respiratory 
maintenance medication (long- and short-acting bronchodila-
tors, xanthines, leukotriene modifiers, oral steroids).
The thresholds were not statistically significantly dif-
ferent from 0 (P-values: 0.466 and 0.338, see Table 2). 
However, the first threshold was significantly lower than the 
second (−0.25075 versus 0.40289, P = 0.0422).
The following variables were not maintained in the final 
model: inhaled corticosteroids, mucolytics, cardiovascular 
medication, courses of antibiotics, most co-morbidities (except 
osteoporosis), and healthcare resource use (emergency room, 
GP consultations).
Predictive performance
Sixty three percent of patients in stage II, 53% of patients 
in stage III and 8% of patients in stage IV were correctly 
identified with the final model (see Table 3A). The overall 
agreement was 53% (unweighted) to 77% (weighted), leading 
to ‘slight’ to ‘fair’ kappa statistics of 0.151 (unweighted) and 
0.230 (weighted).International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
674
Goossens et al
Table 2 Regression results (final model)
Parallel regression assumption 
holds
Parallel regression assumption violated
Shared by both 
dichotomizations
Stages III/IV versus  
stage II
Stage IV versus  
stages II/III
Coefficient P Coefficient P Coefficient P
Age2 −0.00007 0.122 −0.00055 0.000
Male 0.42304 0.000 0.84718 0.000
Underweight (BMI , 18.5) reference category
Low weight (18.5 . BMI , 21) −0.37425 0.110
normal BMI −0.69927 0.001
Overweight (25 , BMI , 30) −0.95891 0.000 −1.77506 0.000
Obese (BMI . 30) −1.18717 0.000 −1.91164 0.000
Current smoker −0.15501 0.097
Osteoporosis 0.33120 0.042
Long-acting bronchodilator 0.26222 0.003
no short-acting bronchodilator reference category
1 short-acting bronchodilator 0.33822 0.001
2 short-acting bronchodilators 0.85445 0.000
Leukotriene modifier 0.66102 0.001
Xanthine 0.61460 0.000 −0.07596 0.706
Oral steroids (maintenance) 0.30360 0.045
no incidental courses of oral steroids reference category
1 course of oral steroids 0.22220 0.037
2 courses of oral steroids 0.29220 0.064
$3 courses of oral steroids 0.21776 0.184
Oxygen 0.75863 0.000 1.59885 0.000
Any hospital admissions in previous year 0.34862 0.081
Threshold −0.25075 0.466 0.40289 0.338
n 2423
Log likelihood −2057.973
Wald test for model significance 0.0000
Abbreviation: BMI, body mass index.
Table 1C health care resource use per GOLD stage in full sample (development and validation sets combined)
Stage II 
n = 1720  
(47%)
III 
n = 1640  
(44%)
IV 
n = 338  
(9%)
P-value*
scheduled GP visits
 0 20.17% 14.82% 12.43% 0.000
 1 18.72% 15.85% 15.09%
 2 23.43% 23.05% 17.75%
  3–4 23.49% 28.78% 31.36%
  $5 14.19% 17.50% 23.37%
Unscheduled GP visits
 0 74.71% 70.12% 64.50% 0.003
 1 13.14% 16.46% 18.64%
 2 6.40% 6.65% 9.17%
  $3 5.76% 6.77% 7.69%
emergency room (no admission)
 0 92.40% 90.47% 89.88% 0.071
 1 4.97% 6.02% 8.04%
  $2 2.63% 3.50% 2.08%
emergency room and admission
 0 91.87% 88.19% 82.74% 0.000
 1 6.26% 9.04% 11.90%
  $2 1.87% 2.77% 5.36%
Direct hospital admissions (yes/no) 3.39% 4.55% 7.14% 0.006
Note: *Two-sided P-values from the chi-squared test for categorical variables.
Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease; GP, general practitioner.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 3A Predictive performance: predicted and observed GOLD stage in validation data set (PPO ordered logit model estimated in 
full development data set)
Predicted GOLD stage Unweighted Weighted
II III IV Total
Observed GOLD stage Overall agreement 53% 77%
II 368 205 7 580 Kappa 0.151 0.230
63% 35% 1% 100% 95% CI 0.103–198 0.196–0.263
III 260 283 4 547
46% 53% 1% 100%
IV 28 82 10 120
24% 68% 8% 100%
Total 656 570 21 1,247
Abbreviations: CI, confidence interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Table 3B Predictive performance: predicted and observed GOLD stage in validation data set (PPO ordered logit model estimated in 
balanced sample) (sensitivity analysis)
Predicted GOLD stage Unweighted Weighted
II III IV Total
Observed GOLD stage Overall agreement 48% 68%
II 64 34 23 121 Kappa 0.215 0.290
53% 28% 19% 100% 95% CI 0.142–0.288 0.205–0.370
III 42 40 38 120
35% 33% 32% 100%
IV 20 32 68 120
17% 27% 57% 100%
Total 126 106 129 361
Abbreviations: CI, confidence interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
The observed values of FEV1%-predicted were slightly 
higher for COPD stage II patients who were correctly clas-
sified by the model than for patients who were incorrectly 
classified (59.4 versus 57.7%, respectively). In stage III, the 
opposite was observed (FEV1%-predicted was 39.4% in the 
correctly classified versus 41.2% in the incorrectly classified), 
and in stage IV , FEV1 was comparable among the correctly 
and incorrectly classified groups (24.9% and 25.6%).
sensitivity analyses
In the balanced sample (regression results not presented), 
agreement was lower for stages II and III than in the unbal-
anced sample, but higher for stage IV: 53%, 33% and 57% 
respectively (Table 3B). The overall agreement was 48% 
(unweighted) to 68% (weighted). The kappa statistics were 
‘fair’ with 0.215 and 0.290, respectively.
In the binary logit model (Table 3C), agreement for 
patients with moderate and severe/very severe COPD was 
54% and 68%. The kappa-statistic was ‘fair’: 0.228.
Discussion
Our study has two important findings. Firstly, the variables 
that were independently related to more severe COPD defined 
by lung function were a lower age, male gender, a lower 
BMI, being an ex-smoker, having osteoporosis, having been 
  hospitalized in the previous year, using oxygen and certain types 
of respiratory maintenance medication (long- and   short-acting 
bronchodilators, xanthines, leukotrien modifiers, oral steroids). 
Other variables expected to be associated with lung function 
impairment, such as other resource use variables, were not 
maintained in the final model. Secondly, the performance of the 
final model was such that the confidence in using the selected 
variables to adjust for COPD severity in the absence of lung 
function parameters was judged to be limited.
Of the variables in the final model, the impact of age 
may be partly due to a healthy survivor effect, whereas long-
acting bronchodilators, multiple short-acting bronchodilators, 
oral steroids and xanthines are clearly indicated for treating 
more advanced stages of COPD. Patients with more severe 
disease are more likely to have quit smoking. A low BMI, 
often associated with loss of muscle mass is well known to 
be more frequent in severe COPD and the higher prevalence 
of osteoporosis might be a side-effect of a long history of 
corticosteroid use.
We used a partial proportional odds model instead of 
the standard ordered logit model. This made it possible to 
estimate different coefficients for the probability of being 
in stage III/IV over stage II than for the probability of being International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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in stage IV, if this was required. The parallel regression 
assumption, which states that the coefficients are equal for 
both dichotomizations, was violated in five instances.
In the final base case model, only 53% of patients were 
classified in the correct GOLD stage. Especially for patients 
in stage IV , the predicted stage was unlikely to be correct (8% 
correct). Results from sensitivity analyses with a more balanced 
sample or a binary logit model were only slightly better.
We chose to present both unweighted and weighted 
kappa statistics. In cases with more than two categories, 
it is customary to weight the kappa-statistics in order to 
penalize disagreements in terms of their seriousness – ie, 
a higher penalty for misclassifying a patient from stage II 
as a stage IV patient than as a stage III patient – whereas 
unweighted kappa treats all disagreements equally. 
  However, in our study all disagreements were considered 
serious and the weighted overall agreement might give an 
overly favorable impression. In the end, the unweighted 
and the weighted kappa statistics were quite similar. Based 
on all values of the kappa statistics, the agreement between 
predicted and observed GOLD stages can be characterized 
as slight to fair.
Several explanations for these findings may be consid-
ered. Firstly, the cut-off points between GOLD stages are 
inevitably somewhat arbitrary and artificial, especially as 
the decline in FEV1 is a continuous process. A patient with a 
FEV1%-predicted of 49% (GOLD stage III) is probably less 
similar to a patient with a value of 31% (also GOLD stage III) 
than to someone with a value of 51% (GOLD stage II). If 
this were an important explanation for our prediction results, 
misclassified patients in stage IV should have markedly bet-
ter lung functions – closer to stage III – than the correctly 
classified patients, while the opposite should be true for 
misclassified patients in stage II. However, the actual differ-
ences in lung function between the correctly and incorrectly 
classified patients in our analysis were small (1.74%-point 
for stage II and 0.66%-point for stage IV).
The second explanation concerns the source of our data, 
which was a clinical trial. It is conceivable that patients with 
very severe disease and many symptoms were less willing 
to participate in the trial. This could then obscure some of 
the associations between disease severity and the predictors. 
This problem would be expected to occur particularly when 
trying to predict GOLD stage IV . However, our models did 
not perform well at distinguishing moderate from severe 
patients either. In the balanced sample analysis, misclas-
sifications occurred equally often in each GOLD stage. 
Furthermore, the proportion of very severe patients in the 
sample does not appear to be low compared to the propor-
tion in the general population of COPD patients in Finland,35 
The Netherlands,36 Greece,37 the United Kingdom,38 and a 
combination of   European and North-American countries.39 
  Moreover, a broad range of patients was allowed to par-
ticipate. For examples, patients were permitted to use all 
respiratory medications concomitantly during the trial except 
inhaled anticholinergic drugs, thus closely resembling routine 
care. Altogether, this protocol makes the UPLIFT a suitable 
trial for this study.
The third explanation would be the far from perfect asso-
ciation of resource use, which is often driven by symptoms 
and exacerbations, with GOLD stage. Patients with a rela-
tively good lung function do not necessarily experience fewer 
symptoms than patients with worse lung function. Indeed, the 
UPLIFT sample contains a non-negligible number of patients 
with very severe COPD who do use little or no maintenance 
medication, as well as patients with moderate disease who 
use four or five different types of medications. Overall, we 
observed an independent association of GOLD stage with 
several respiratory medications, but not with other types of 
resource use such as ER visits and physician consults in our 
multivariable model, which was not expected beforehand. 
In univariate analyses, patients with more severe COPD 
were more likely to have higher COPD-related resource use 
(almost all types of medication use, courses of oral steroids 
Table 3C Predictive performance: predicted and observed GOLD stage in validation data set (Binary logit model estimated in development 
data set)
Predicted GOLD stage Unweighted
II III/IV Total
Observed GOLD stage Overall agreement 62%
II 316 264 585 Kappa 0.228
54% 46% 100% 95% CI 0.173–0.284
III/IV 212 455 667 c-statistic 0.614
32% 68% 100% 95% CI 0.587–0.640
Total 528 719 1,247
Abbreviations: CI, confidence interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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and antibiotics, scheduled and unscheduled GP visits and 
hospital admissions with and without visits to the emergency 
room), not to use statins and other cardiovascular medication, 
to be younger, male, underweight, ex-smoker, and suffer 
from osteoporosis.
Several database studies have attempted to adjust for 
possible differences in COPD severity in the absence of 
lung function data. In an article comparing the assessment of 
COPD patients in the UK General Practice Research Data-
base with the clinical opinion of the patient’s GP, Soriano 
et al19 based their severity classification on medication use. 
Sin and Tu20 assessed the effects of ICS use on mortality and 
applied medication use, ER visits and physician services as 
proxies of disease severity. Similarly, Suissa21 adjusted only 
for age, sex and medication use. Breekveldt-Postma et al22 
identified determinants of patient’s persistence with ICS 
therapy. They considered hospital admissions and medica-
tion use to be proxies for disease severity. In a study relating 
COPD severity with cardiovascular disease, Curkendall 
et al23 assumed that COPD severity could be defined as 
the likelihood of being hospitalized, given the relationship 
with mortality. They concluded that this probability of hos-
pitalization is associated with medication and oxygen use, 
previous hospitalizations, recent exacerbations, pneumonia 
and lung emphysema. Griffin et al24 assessed the effects of 
tiotropium compared to combined ipratropium and salbuta-
mol on exacerbations and hospitalizations. They adjusted for 
a combination of resource use data and risk factors. Based 
on the current analyses, we conclude that the variables used 
in these database studies cannot be relied upon to adequately 
adjust for COPD severity in terms of lung function.
Conclusion
Data from a well-controlled trial setting indicated that COPD 
severity defined by lung function thresholds cannot be reli-
ably predicted from patient characteristics and their previous 
healthcare use. This limitation should be considered when 
interpreting findings from database studies, and additional 
research should explore other methods allowing accounting 
for COPD severity.
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